Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management

References

• Patruno C, Amerio P, Chiricozzi A, Costanzo A, Cristaudo A, Cusano F, Foti C, Girolomoni G, Guarneri F, Naldi L, et al. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian society of dermatology and venereology (SIDeMaST), Italian association of hospital dermatologists (ADOI), and Italian society of allergological, occupational and environmental dermatology (SIDAPA). G Ital Dermatol Venereol. 2020;155(1):1–7. doi:10.23736/S0392-0488.19.06522-2.
   PubMed Web of Science ®Google Scholar
• Naldi L, Parazzini F, Gallus S. GISED study centres. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. Acta Derm Venereol. 2009;89(2):122–25. doi:10.2340/00015555-0591.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;1396(10247):345–60. doi:10.1016/S0140-6736(20)31286-1. PMID: 32738956.
   Google Scholar
• Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin Infect Dis. 2012;54(6):832–40. doi:10.1093/cid/cir952. PMID: 22291103.
   PubMed Web of Science ®Google Scholar
• Schneider L, Weinberg A, Boguniewicz M, Taylor P, Oettgen H, Heughan L, Zaccaro D, Armstrong B, Holliday A, Leung DY. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol. 2010 Dec;126(6):1306–7.e2. doi:10.1016/j.jaci.2010.08.010. PMID: 20889193.
   PubMed Web of Science ®Google Scholar
• Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R, Paller AS, Lieff S, Reese J, Zaccaro D, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260–69. doi:10.1016/j.jaci.2009.05.020.
   PubMed Web of Science ®Google Scholar
• Slifka MK, Leung DY, Hammarlund E, Raué HP, Simpson EL, Tofte S, Baig-Lewis S, David G, Lynn H, Woolson R, et al. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis. J Allergy Clin Immunol. 2014;133(2):439–47. doi:10.1016/j.jaci.2013.10.037. PMID: 24331381.
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics. 1975 Mar;55(3):342–47. PMID: 238178.
   PubMed Web of Science ®Google Scholar
• Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med. 1969 Nov 27;281(22):1201–08. doi:10.1056/NEJM196911272812201. PMID: 4186802.
   PubMed Web of Science ®Google Scholar
• Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis. 1970 Oct;122(4):303–09. doi:10.1093/infdis/122.4.303. PMID: 4396189.
   PubMed Web of Science ®Google Scholar
• Henderson DA. Smallpox: clinical and epidemiologic features. Emerg Infect Dis. 1999 Jul;5(4):537–39. doi:10.3201/eid0504.990415. PMID: 10458961.
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines. 2008 Oct;7(8):1225–37. doi:10.1586/14760584.7.8.1225. PMID: 18844596.
   PubMed Web of Science ®Google Scholar
• Engler RJ, Kenner J, Leung DY. Smallpox vaccination: risk considerations for patients with atopic der- matitis. J Allergy Clin Immunol. 2002 Sep;110(3):357–65. doi:10.1067/mai.2002.128052. PMID: 12209080.
   PubMed Web of Science ®Google Scholar
• Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, Gerber SI, Garcia-Houchins S, Lederman E, Hruby D, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008 May 15;46(10):1555–61. doi:10.1086/587668. PMID: 18419490.
   PubMed Web of Science ®Google Scholar
• Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY. Cytokine milieu of atopic der- matitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006 Mar;24(3):341–48. doi:10.1016/j.immuni.2006.02.006. PMID: 16546102.
   PubMed Web of Science ®Google Scholar
• Copeman P, Wallace HJ. Eczema vaccinatum. Br Med J. 1964;5414:906–08. doi:10.1136/bmj.2.5414.906. PMID: 14185655.
   Web of Science ®Google Scholar
• Greenberg RN, Hurley MY, Dinh DV, Mraz S, Vera JG, von Bredow D, von Krempelhuber A, Roesch S, Virgin G, Arndtz-Wiedemann N, et al. A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18–40 year old subjects with diagnosed atopic dermatitis. PLoS One. 2015 Nov 10;10(11):e0142802. doi:10.1371/journal.pone.0138348. eCollection 2015. PMID: 26439129.
   PubMed Web of Science ®Google Scholar
• Patel DP, Treat JR, Castelo-Socio L. Decreased Hepatitis B vaccine response in pediatric patients with atopic dermatitis, psoriasis, and morphea. Vaccine. 2017 Aug 16;35(35Pt B):4499–500. doi:10.1016/j.vaccine.2017.07.025. Epub 2017 Jul 20. PMID: 28736199.
   PubMed Web of Science ®Google Scholar
• Farooqi IS, Hopkin JM. Early childhood infection and atopic disorder. Thorax. 1998 Nov;53(11):927–32. doi:10.1136/thx.53.11.927. PMID: 10193389.
   PubMed Web of Science ®Google Scholar
• Oszukowska M, Michalak I, Gutfreund K, Bienias W, Matych M, Szewczyk A, Kaszuba A. Role of primary and secondary prevention in atopic dermatitis. Postepy Dermatol Alergol. 2015 Dec;32(6):409–20. doi:10.5114/pdia.2014.44017. Epub 2015 Dec 11. PMID: 26755903.
   PubMed Web of Science ®Google Scholar
• Grüber C. Childhood immunisations and the development of atopic disease. Arch Dis Child. 2005 Jun;90(6):553–55. doi:10.1136/adc.2004.061960. PMID: 15908611.
   PubMed Web of Science ®Google Scholar
• Gehrt L, Rieckmann A, Kiraly N, Jensen AKG, Aaby P, Benn CS, Sørup S, Timeliness of DTaP-IPV-Hib vaccination and development of atopic dermatitis between 4 months and 1 year of age-register-based cohort study. J Allergy Clin Immunol Pract. 2020 Oct 2;S2213-2198(20)31002–3. doi:10.1016/j.jaip.2020.09.024. Epub 2020 Oct 2. PMID: 33011301.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Black S, Rappuoli R. Emerging infectious diseases: a proactive approach. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4055–59. doi:10.1073/pnas.1701410114. Epub 2017 Apr 10.
   PubMed Web of Science ®Google Scholar
• Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963. doi:10.3389/fimmu.2018.01963. eCollection 2018. PMID: 30283434.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019 Apr 10; 27(4):757–72. doi:10.1016/j.ymthe.2019.01.020. Epub 2019 Feb 7. PMID: 30803823.
   PubMed Web of Science ®Google Scholar
• Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW. Self-amplifying mRNA vaccines. Adv Genet. 2015;89:179–233. doi:10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4. PMID: 25620012.
   PubMed Web of Science ®Google Scholar
• Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, et al. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2013;2:e52. doi:10.1038/emi.2013.54. Epub 2013 Aug 14. PMID: 26038486.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–51. doi:10.1038/nature21428. Epub 2017 Feb 2.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;169:176. doi:10.1016/j.cell.2017.02.017. Epub 2017 Feb 17. PMID: 28222903.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Mansoura MK, Geall AJ. Vaccines ‘on demand’: science fiction or a future reality. Expert Opin Drug Discov. 2015;10:101–06. doi:10.1517/17460441.2015.996128. Epub 2015 Jan 13. PMID: 25582273.
   PubMed Web of Science ®Google Scholar
• Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020 Dec;41(12):1100–15. doi:10.1016/j.it.2020.10.004. Epub 2020 Oct 14. PMID: 33132005.
   PubMed Web of Science ®Google Scholar
• Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020 Nov 25;10:587269. doi:10.3389/fcimb.2020.587269. eCollection 2020. PMID: 33324574.
   PubMed Web of Science ®Google Scholar
• Assessment report COVID-19 vaccine comirnaty. www.ema.europa.eu .
   Google Scholar
• Real-world evidence confirms high effectiveness of pfizer-biontech covid-19 vaccine and profound public health impact of vaccination one year after pandemic declared. [accessed 2021 Mar 11]. Businesswire.com .
   Google Scholar
• Assessment report COVID-19 Vaccine Moderna. [ accessed 2021 Apr 2]. www.ema.europa.eu .
   Google Scholar
• Gsell PS, Camacho A, Kucharski AJ, Watson CH, Bagayoko A, Nadlaou SD, Dean NE, Diallo A, Diallo A, Honora DA, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017 Dec;17(12):1276–84. doi:10.1016/S1473-3099(17)30541-8. Epub 2017 Oct 9. Erratum in: Lancet Infect Dis. 2017 Dec;17 (12): 1232.PMID: 29033032; PMCID: PMC5700805.
   PubMed Web of Science ®Google Scholar
• Assessment report COVID-19 Vaccine AstraZeneca. [ accessed 2021 Apr 2]. www.ema.europa.eu .
   Google Scholar
• COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB. [ accessed 2021 Apr 2]. www.ema.europa.eu .
   Google Scholar
• Assessment report COVID-19 vaccine Janssen, [ accessed 2021 Apr 2]. www.ema.europa.eu .
   Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Gam-COVID-vac vaccine trial group. safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20;397(10275):670.PMID: 33545094; PMCID: PMC7852454.
   PubMed Web of Science ®Google Scholar
• Leung DYM, Jepson B, Beck LA, Hanifin JM, Schneider LC, Paller AS, Monti K, David G, Canniff J, Lorenzo MG, et al. A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with pic dermatitis. J Allergy Clin Immunol. 2017 May;139(5):1575–1582.e8. doi:10.1016/j.jaci.2016.12.952. Epub 2017 Feb 13. PMID: 28209343.
   PubMed Web of Science ®Google Scholar
• Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005 Feb;52(2):247–53. doi:10.1016/j.jaad.2004.08.046. PMID: 15692469.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495–504. doi:10.1067/mjd.2002.122187. PMID: 11907497.
   PubMed Web of Science ®Google Scholar
• Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti- inflammatory drug. J Allergy Clin Immunol. 2002;110:277–84. doi:10.1067/mai.2002.126500. PMID: 12170269.
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, et al. Efficacy and safety of pimecrolimus cream in the long- term management of atopic dermatitis in children. Pediatrics. 2002;110:1–8. doi:10.1542/peds.110.1.e2. PMID: 12093983.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005 Aug;53(2Suppl 2):S206–13. doi:10.1016/j.jaad.2005.04.064. PMID: 16021176.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines (Basel). 2020 Dec 16;8(4):769. doi:10.3390/vaccines8040769. PMID: 33339348.
   PubMed Web of Science ®Google Scholar
• Crowe SR, Merrill JT, Vista ES, Dedeke AB, Thompson DM, Stewart S, Guthridge JM, Niewold TB, Franek BS, Air GM, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011;63:2396–406. doi:10.1002/art.30388. PMID: 21598235.
   PubMed Web of Science ®Google Scholar
• Palestine AG, Roberge F, Charous BL, Lane HC, Fauci AS, Nussenblatt RB. The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans. J Clin Immunol. 1985;5:115–21. doi:10.1007/BF00915009. PMID: 3872878.
   PubMed Web of Science ®Google Scholar
• Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation. 1986;42:376–79. doi:10.1097/00007890-198610000-00009. PMID: 3532450.
   PubMed Web of Science ®Google Scholar
• Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019 Jan/Feb;23(1):50–74. doi:10.1177/1203475418811335. Epub 2018 Nov 21. PMID: 30463418.
   PubMed Web of Science ®Google Scholar
• Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010 Feb 9;3(1):8–18. doi:10.6030/1939-067x-3.1.8. PMID: 21423788.
   PubMedGoogle Scholar
• Novartis Pharmaceuticals Canada, Inc. NEORAL [product monograph]; 2015 Jan 9.
   Google Scholar
• Sanofi-Aventis Canada, Inc. PEDIAPRED [product monograph]; 2006 May 1.
   Google Scholar
• Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014 Jul 10;371(2):130–39. doi:10.1056/NEJMoa1314768. PMID: 25006719.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2020 Jul 3;1–4. doi:10.1080/09546634.2020.1773379. Online ahead of print. PMID: 32436765.
   Web of Science ®Google Scholar
• Simonetti O, Radi G, Diotallevi F, Molinelli E, Rizzetto G, Offidani A. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience. Clin Exp Dermatol. 2021 Feb 12. doi:10.1111/ced.14611. Online ahead of print. PMID: 33576497.
   PubMed Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Campo I, Casas M. Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients. Dermatol Ther. 2020 Nov; 33(6):e14172. doi:10.1111/dth.14172. Epub 2020 Sep 5. PMID: 32779378.
   PubMed Web of Science ®Google Scholar
• Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. Dupilumab and COVID-19: what should we expect? Dermatol Ther. 2020 Jul;33(4):e13502. doi:10.1111/dth.13502. Epub 2020 May 20. PMID: 32362061.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303–e304. doi:10.1111/jdv.16527. Epub 2020 Jun 8. PMID: 32330323.
   PubMed Web of Science ®Google Scholar
• Simonetti O, Rizzetto G, Molinelli E, Diotallevi F, Radi G, Cirioni O. Safety and efficacy of vaccines during COVID-19 pandemic in patients treated with biological drugs in a dermatological setting. Healthcare. 2021;9(4):401. doi:10.3390/healthcare9040401.
   Web of Science ®Google Scholar
• Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):158–167.e1. doi:10.1016/j.jaad.2018.07.048. Epub 2018 Aug 6. PMID: 30092324.
   PubMed Web of Science ®Google Scholar
• Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020 Nov 16;9:2020-8-5. doi:10.7573/dic.2020-8-5. eCollection 2020. PMID: 33240390.
   PubMedGoogle Scholar
• El Hachem M, Gesualdo F, Ricci G, Diociaiuti A, Giraldi L, Ametrano O, Occella C, Fortina AB, Milioto M, Arcangeli F, et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43:22. doi:10.1186/s13052-017-0330-7. PMID: 28245844.
   PubMed Web of Science ®Google Scholar